Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Indiplon-IR: Phase I data

In a double-blind, cross-over Phase I trial in 35 healthy volunteers, Indiplon IR was well tolerated and did not produce

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE